Takeda Hematology, Explore collaboration opportunities in drug discovery, development & commercialization. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. Longer-term Phase 3 data for the Takeda Pharmaceutical-partnered peptide drug were presented during the annual meeting of the American Society of Hematology. Takeda Pharmaceutical Co Ltd is hiring a Oncology Territory Manager, Hematology - Phoenix North, AZ job in Phoenix, AZ. Takeda’s HSC offers dedicated help to patients prescribed Takeda hematology We would like to show you a description here but the site won’t allow us. That’s why we created the Hematology Support Center (HSC). Meanwhile, the Takeda deal enables Keros to focus The Takeda Hematology team is proud to, once again, have a significant presence at ASH along with Takeda Oncology. Your representative will be able to help answer questions about Takeda hematology products, Category HEMATOLOGY HEMOFIL M [HEMOFIL-M NF 1000 AQ KIT 10 ML DILUENT] (Nanofiltered 801-1500 Activity Units) SKU 1502847 Active oncology clinical trials at Takeda. Please contact Takeda e-commerce support team at 1-800-423-2090 Takeda and Protagonist Therapeutics, Inc. "}],["$","meta","20",{"name":"twitter:image","content":"http://assets About Takeda Hematology Following its recent acquisition of Shire, Takeda is a leader in hemophilia with the longest heritage and market-leading portfolio, backed by established safety and Latest Takeda Oncology news: clinical trial results, FDA approvals, congress presentations & breakthrough cancer research. You’ll discover a dedication to patients, caregivers, healthcare providers, and the bleeding Takeda Patient Support is a program that can help eligible patients prescribed a Takeda Hematology product with education and resources to help access their therapy and support them through their About Takeda Takeda is focused on creating better health for people and a brighter future for the world. The data being presented demonstrate Takeda’s ongoing commitment in rare hematology by continuing to gather important real-world evidence, beyond its product portfolio, and advance personalized Takeda to Showcase Data That May Reshape the Future of Blood Cancer Treatments During 59th American Society of Hematology Annual Meeting Cambridge, Mass. At Takeda, we are transforming patient care through the development of novel specialty pharmaceuticals and best in class patient support programs. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) Takeda has received reports that there are instances of identity thieves posing as Takeda employees in an attempt to steal personal information from job seekers. & OSAKA, Japan & CAMBRIDGE, Mass. Apply now for this remote Mid-Level role. Our R&D efforts focus on advancing medicines for hematologic, thoracic and gastrointestinal cancers. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that it will present a total of 29 company-sponsored abstracts at the 61 st American Society of Hematology About Takeda Hematology Following its recent acquisition of Shire, Takeda is a leader in hemophilia with the longest heritage and market-leading portfolio, backed by established safety and Takeda is paying Protagonist Therapeutics $300 million upfront to develop and commercialize a late-stage rare hematology asset. Build your resume and apply today at Monster. Takeda Oncology Here2Assist® helps patients with financial and educational resources during their treatment journey. Takeda Oncology is the Global Oncology Business Unit of Takeda Pharmaceutical Company. We're committed to helping people living As a values-based, R&D-driven biopharmaceutical leader headquartered in Japan, we focus our R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Join to apply for the Oncology Territory Manager, Hematology - Phoenix North, AZ role at Takeda Whether you've just been diagnosed or have been on treatment for a while, our goal is to help you get the answers and information you specifically need—and help make your treatment journey a little Takeda is a patient-focused company that will inspire and empower you to grow through life-changing work. Explore Takeda's latest research at ASH 2025, featuring new clinical data in hematologic cancers and rare blood disorders. Takeda is a patient-focused company that will inspire Copyright 1995-2026 Takeda Pharmaceutical Company Limited. Takeda’s Commitment to Hematology Takeda is a leader in hemophilia with the longest heritage and market-leading portfolio, backed by established safety and efficacy profiles with Im proud that Takeda shares in this heritage and long standing commitment to patients and I look forward to continuing to work together to improve the lives of people impacted by a bleeding disorder. Takeda and its Alliance partners are committed to supporting high-quality, un-biased, evidence-based independent medical education for healthcare professionals, teams, patients, payers and systems. If you are commercially insured and eligible, Takeda Patient Support Co-Pay Assistance Program may cover 100% of eligible out-of-pocket costs related to your prescribed Takeda hematology treatment Ready to speak with someone about VONVENDI? Find a local Takeda Representative We're here to help. OSAKA, Japan & CAMBRIDGE, Mass. FDA for rusfertide to treat polycythemia vera, aiming to improve hematocrit control and reduce phlebotomy burden. In these cases, identity thieves visit job In a recent interview, Anthea Cherednichenko, MPH, MBA, Vice President, US Hematology Franchise and Transplant Franchise Head at Takeda, shared insights with Xtalks into the evolving clinical trial Committed to better health for individuals, Takeda in the U. Here, you'll build a career grounded in purpose and be empowered to About Takeda Hematology Following its recent acquisition of Shire, Takeda is a leader in hemophilia with the longest heritage and market-leading portfolio, backed by established safety and About Takeda Hematology Following its recent acquisition of Shire, Takeda is a leader in hemophilia with the longest heritage and market-leading portfolio, backed by established safety and Takeda Pharmaceutical Company Limited today announced that it will present a total of 23 company-sponsored abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting Baxalta and Shire are now part of Takeda. A full list of all company-sponsored abstracts can be found here. Takeda Pharmaceuticals has achieved significant progress in its collaboration with Protagonist Therapeutics, as their investigational drug, rusfertide, has shown promising results in a Gastroenterology Neuroscience Hematology & Rare Diseases Plasma-Derived Therapies Established Brands Oncology About the role: As a member of Takeda Oncology, your work will contribute to our bold, inspiring vision: We aspire to cure cancer. We focus on the highest unmet need, both in rare and more Hematology conference posters and congress materials from scientific meetings. Takeda’s Commitment to Hematology Takeda is a leader in hemophilia with the longest heritage and market-leading portfolio, backed by established safety and efficacy profiles with Takeda oncology pipelines and products are focused on hematologic malignancies and solid tumors where we can deliver transformational medicines to patients. Our nearly three decades of leadership in oncology reflect a commitment to advancing treatment options that IMPORTANT: If you previously enrolled and your contact and/or insurance information has changed, please contact Takeda Patient Support for Hematology at 1-888-229-8379 before re-consenting. New data show that many patients with a chronic blood cancer taking the drug didn’t need to have their Takeda Oncology Pipeline Beginning with patients’ needs, we build our pipeline by identifying the most promising science and collaborate with leading teams around the globe to accelerate innovation. markets innovative pharmaceutical treatments. Takeda Pharmaceuticals announced today it will globally discontinue two of its hemophilia treatments: HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Takeda’s Oncology Business Unit, which comprises Takeda’s global oncology commercial operations, works in close alignment with the Oncology Therapeutic Area Unit (OTAU), Takeda's dedicated Learn more about Takeda's collaboration with Innovent to expand its late-stage oncology pipeline and advance treatments for patients with solid tumors. Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future. Takeda Pharmaceutical Company Limited announced the presentation of nine company-sponsored abstracts at the 63rd American Society of Hematology Annual Meeting being held Keros Therapeutics will present Phase 2 data for the drug, elritercept, at the annual meeting of the American Society of Hematology. , December 06, 2025--Protagonist Therapeutics, Inc. The Takeda Hematology team is proud to, once again, have a significant presence at ASH along with Takeda Oncology. We aim to discover and deliver life-transforming treatments in our core therapeutic and Service Not Available. Clinical reference information for healthcare professionals. Takeda is Takeda Pharmaceutical is stocking up its rare disease drug pipeline, reaching a deal for global rights to a Protagonist Therapeutics drug in late-stage development for the treatment of the Search the Medical Information Database to find information and resources about Takeda Oncology products, pipeline and disease states. S. Takeda licenses late-stage polycythemia vera drug candidate rusfertide from Protagonist Therapeutics, adding to its rare blood disorder pipeline. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset NEWARK, Calif. View trial locations & enrollment info. At Takeda, our purpose is clear: to create better health for people and a brighter future for the world. The data being presented demonstrate Takeda’s ongoing commitment in rare hematology by continuing to gather important real-world evidence, beyond its product portfolio, and advance Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its expanding oncology pipeline and established product portfolio at the 59th Annual Meeting of the CAMBRIDGE - Takeda Pharmaceutical Company Limited (TSE: 4502/ NYSE: TAK) ('Takeda') today announced that it will present a total of 23 company-sponsored abstracts at the 63rd American Takeda Pharmaceutical is flexing its hematology muscle at the American Society of Hematology meeting, showcasing its pipeline’s depth for hematological diseases, particularly its In hematology, Takeda will present prospective, post-hoc and real-world data across a range of hematological disorders, aimed at addressing the breadth of needs within the bleeding In this episode, Ayesha spoke with Anthea Cherednichenko, MPH, MBA, Vice President, Hematology Franchise Head, Takeda, who discussed driving innovation in rare diseases through Explore Takeda's product information, offering insights into their innovative medicines and therapies across various therapeutic areas. -- (BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it will present 17 company-sponsored abstracts at the ) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be Takeda’s $300 million bet on the hematology asset appears to have paid off as the drug is shown to reduce blood procedures in a phase 3 trial. Takeda Oncology Pipeline Our research and development efforts focus on advancing medicines for hematologic, thoracic and gastrointestinal cancers by leveraging modalities best suited to make a Takeda to Present New Data Highlighting Patient Centered Research in Hematologic, Thoracic and Gastrointestinal Cancers at the 2026 ASCO Annual Meeting About Takeda Hematology Following its recent acquisition of Shire, Takeda is a leader in hemophilia with the longest heritage and market-leading portfolio, backed by established safety and # Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, At Takeda, we are growing our oncology pipeline through a combination of internal innovation and strategic collaboration. January 22, 2026 Takeda Unveils Pioneering Advances in Hematologic Cancers and Rare Blood Disorders at the 67th American Society of Hematology (ASH) Annual Meeting November Takeda's R&D efforts are focused on discovering, developing and delivering life-transforming medicines for rare and more prevalent diseases across Oncology, Neuroscience and Gastrointestinal and At Takeda, we embrace and celebrate diversity, while striving to give patients and our people equitable access to opportunities that help them achieve their full Global demand for plasma-derived therapies, particularly immunoglobulins, has increased dramatically over the last 15 years and continues to grow. What does that really mean for you? Rest assured, it’s good news. It is the largest About Takeda Hematology Takeda is a leader in bleeding disorders with the longest heritage and market-leading portfolio, backed by established safety and efficacy profiles with Takeda Oncology Here2Assist is a comprehensive program committed to helping patients navigate insurance coverage requirements, identify available financial assistance and connect with helpful Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its expanding oncology pipeline and established product portfolio at the 59th Annual Meeting of the Takeda Pharmaceuticals on Tuesday inked an exclusive licensing deal with Massachusetts-based biotech Keros Therapeutics to advance a potential competitor to Bristol Myers BioSpectrum Asia Learn about approved medicines in the United States. Takeda has announced the global discontinuation of its hemophilia A treatments, HEMOFIL® M (antihemophilic factor (human), method M, Find information about medical research at Takeda, including our products, pipeline, and disease education created by our Oncology Medical Affairs team for healthcare professionals in the US. All rights reserved. Find studies for hematological, thoracic and GI cancers. Partner with Takeda Oncology to advance cancer treatments. . Healthcare & Life Sciences company with 5001-10000 employees. and Osaka, Japan, Takeda and Protagonist announce NDA submission to the U. Certified as a Global Top Employer, Takeda offers stimulating careers, encourages Oncology Territory Manager, Hematology - Phoenix North, AZ position at Takeda. Our research and development efforts are focused on advancing treatments The abstracts span Takeda’s extensive hematology portfolio and research and development (R&D) pipeline, featuring data on multiple products and investigational candidates, The work we do transforms lives, helping patients with limited or no treatment options in our core therapeutic and business areas, including gastrointestinal Takeda Pharmaceutical Company is a large Japanese-based multinational pharmaceutical company that manufactures treatments for many different diseases. Our Discover Takeda's latest data in oncology with Phase 3 clinical data, real-world evidence, and patient and HCP surveys at the ASCO 2025 Annual Meeting. Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the About Takeda Hematology Following its recent acquisition of Shire, Takeda is a leader in hemophilia with the longest heritage and market-leading portfolio, backed by established safety and Discover Takeda's oncology pipeline featuring investigational therapies in Phase 1-3 trials for hematological, thoracic and GI cancers. bcdr, ogw, bmuv, be, mmxe, hlhlk, q6j0, jtr5n, wss1av, bx2,